Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Canbridge Pharmaceuticals's enterprise value is €111.45 Mil.
Canbridge Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.51 Mil. Therefore, Canbridge Pharmaceuticals's EV-to-EBITDA for today is 31.79.
The historical rank and industry rank for Canbridge Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
FRA:MF1'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.54 Med: -0.42 Max: 41.72
Current: 32.08
During the past 7 years, the highest EV-to-EBITDA of Canbridge Pharmaceuticals was 41.72. The lowest was -3.54. And the median was -0.42.
FRA:MF1's EV-to-EBITDA is ranked worse than 73.43% of 399
companies
in the Biotechnology industry
Industry Median: 13.39
vs FRA:MF1: 32.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Canbridge Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Canbridge Pharmaceuticals's share price for today is €0.173.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MF1 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Canbridge Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's EV-to-EBITDA falls into.
Canbridge Pharmaceuticals's current Enterprise Value is €111.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (FRA:MF1) has a EV-to-EBITDA of 31.79 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Canbridge Pharmaceuticals. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #293 out of 399 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Canbridge Pharmaceuticals' EV-to-EBITDA too high?
Canbridge Pharmaceuticals' current EV-to-EBITDA is 31.79. The Biotechnology industry median EV-to-EBITDA is 13.39. Canbridge Pharmaceuticals' value of 31.79 is 137.4% above this industry median. Based on the distribution chart, Canbridge Pharmaceuticals ranks #293 out of 399 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #293 out of 399 companies for EV-to-EBITDA. This places Canbridge Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.39. Canbridge Pharmaceuticals' value of 31.79 is 137.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.39, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canbridge Pharmaceuticals's current EV-to-EBITDA of 31.79 is 137.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Canbridge Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 13.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canbridge Pharmaceuticals's current EV-to-EBITDA is 31.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Canbridge Pharmaceuticals (FRA:MF1) has a current EV-to-EBITDA of 31.79. The stock's GF Value™ is €0.03, compared to a current price of €0.17 — trading 476.7% above its estimated fair value. The current EV-to-EBITDA is 31.79 and 137.4% above the Biotechnology industry median of 13.39. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Canbridge Pharmaceuticals (FRA:MF1), the current EV-to-EBITDA is 31.79 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.17 is trading 476.7% above its estimated GF Value™ of €0.03.
Key valuation signals for FRA:MF1:
EV-to-EBITDA: 31.79
GF Value™: €0.03 vs. price of €0.17 (476.7% above fair value)
Industry Position: 137.4% above the Biotechnology median (#293 of 399)
No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for FRA:MF1
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MF1 has been successfully added to your 
